Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render

ADCs

Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC

The FDA initially placed the Phase III IDeate-Lung02 study on hold due to a “higher than expected” number of deaths in patients treated with ifinatamab deruxtecan.

January 13, 2026

3 min read

Tristan Manalac

Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration

Manufacturing

AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.

January 13, 2026

2 min read

Tristan Manalac

FDA signage at its headquarters in Maryland

Manufacturing

AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the reshoring of pharmaceutical manufacturing.

January 13, 2026

5 min read

Nick Paul Taylor

abstract image of DNA, tablets and planet earth. 3D-image

Policy

At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’

Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.

January 12, 2026

4 min read

Dan Samorodnitsky

Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration

Collaboration

JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.

January 12, 2026

3 min read

Annalee Armstrong

AbbVie's office in South San Francisco, California

Cancer

AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market

The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.

January 12, 2026

2 min read

Nick Paul Taylor

Business

Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.

January 12, 2026

2 min read

Nick Paul Taylor

Red engraving brain illustration in top view isolated on blue background

Alzheimer’s disease

Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro

The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.

January 12, 2026

2 min read

Tristan Manalac